Beyondspring Inc. (BYSI) Stock Price & Analysis
Beyondspring Inc. (BYSI) rose 3.70% to USD 1.12 as of July 25, 2026 at 04:19 UTC, according to Nexqual real-time market data.
BYSI last closed at USD 1.08; the session ranged USD 1.1–1.16 on volume of 35,917 shares. Market capitalization is $46.05M, with a 52-week range of USD 0.99–2.44 (NCM). Source: Nexqual, July 25, 2026 at 04:19 UTC.
Key Statistics (as of July 25, 2026 at 04:19 UTC)
| Price | USD 1.12 |
|---|---|
| Change | ▲ 3.70% (up) |
| Previous Close | USD 1.08 |
| Open | USD 1.1 |
| Day Range | USD 1.1 – 1.16 |
| 52-Week Range | USD 0.99 – 2.44 |
| Volume | 35,917 shares |
| Market Cap | $46.05M |
| Exchange | NCM |
Technical Analysis (BYSI)
Nexqual's technical model rates BYSI "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 26.1 (oversold) |
| vs SMA50 | Below (USD 1.54) |
| MACD | -0.14 (negative) |
Analyst Ratings (BYSI)
Wall Street analysts rate BYSI "None", per Nexqual as of July 25, 2026 at 04:19 UTC.
| Consensus Rating | None |
|---|
Earnings (BYSI)
| Next Earnings Date | 2026-08-12 |
|---|
Source: Nexqual, July 25, 2026 at 04:19 UTC.
Financials & Fundamentals (BYSI)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 1.09 |
| Total Cash | $7.86M |
| Total Debt | $246,000 |
| Free Cash Flow | $12.37M |
Source: Nexqual, July 25, 2026 at 04:19 UTC.
Financial Health Score (BYSI)
Nexqual rates Beyondspring Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 04:19 UTC.
| Growth | Mixed — Revenue +0.0% YoY (annual), slow |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $8M cash, no debt |
| Cash Flow | Strong — FCF $12M, 916% margin |
| Efficiency | Mixed — No data |
Ownership (BYSI)
| Insider Ownership | +14.26% |
|---|---|
| Institutional Ownership | +14.58% |
| Shares Outstanding | 41.12M |
| Float | 31.95M |
| Short % of Float | +6.51% |
Source: Nexqual, July 25, 2026 at 04:19 UTC.
Leadership (BYSI)
Beyondspring Inc. is led by Min Qiu (age 42), Chief Executive Officer, per Nexqual as of July 25, 2026 at 04:19 UTC.
| Chief Executive Officer | Min Qiu (age 42) |
|---|---|
| Chief Scientific Officer | June Lu (age 59) |
| Chief Financial Officer | Li Na (age 48) |
| Senior Vice President of Development | John Mao |
| Vice President of Finance | Joy Jia |
Major Backers & Investors (BYSI)
Notable institutional backers of Beyondspring Inc. include Decheng Capital LLC, Fidelity, according to Nexqual as of July 25, 2026 at 04:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Decheng Capital LLC | 9.24% |
| Fidelity | 0.72% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.4% |
| BlackRock | 1.77% |
| Geode Capital | 0.91% |
| State Street | 0.56% |
| Northern Trust | 0.17% |
Source: Nexqual, July 25, 2026 at 04:19 UTC.
From Beyondspring Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology.
- The company operates through two segments: the Plinabulin pipeline and the TPD platform.
- The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN).
- It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FULC | Fulcrum Therapeutics, Inc. | USD 3.72 | ▲ 0.54% |
| VRPX | Virpax Pharmaceuticals, Inc. | USD 0 | ▼ 75% |
| GRTXD | Galera Therapeutics, Inc. | USD 17.5 | ▲ 7.64% |
| ATXI | Avenue Therapeutics, Inc. | USD 0.28 | ▲ 2.22% |
| IPHA | Innate Pharma S.A. | USD 1.78 | ▲ 0.28% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:19 UTC. This page is informational and not investment advice.